RxDoctor Payments Data

Lee Bee

Internal Medicine · Clayton, MONPI 1669429908

Payments from drug & device makers

$2,311in general payments, 2019–2025

Across 89 payments — averaging $25.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$582
  • Bayer$522
  • Otsuka America Pharmaceutical, Inc.$219
  • Regeneron Healthcare Solutions, Inc.$167
  • Novo Nordisk$166
  • AstraZeneca$165
  • plus $490 from 13 others

What the payments were for

  • Consulting fees$40017%
  • Food & beverage$1,85080%
  • Education$613%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,311 in reported general payments places this provider in the 80th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$36,762
Medicare patients
81
Services billed
353

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban58$12,610
Memantine Hcl117$6,385
Diltiazem 24hr Er (Cd)Diltiazem Hcl13$1,121
Rosuvastatin Calcium33$901
Gabapentin64$744
Losartan Potassium45$726
Pioglitazone Hcl35$708
Olanzapine44$651
Carbidopa-LevodopaCarbidopa/Levodopa15$599
Donepezil Hcl26$509
Divalproex Sodium11$471
Torsemide30$440
Sertraline Hcl62$437
Lisinopril31$420
Amlodipine Besylate39$393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$54$65144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Clayton

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →